Respironics inked an agreement with The State University of New York (SUNY) and New York University School of Medicine (NYU) to utilize the I-neb Adaptive Aerosol Delivery (AAD®) system for clinical evaluation of aerosolized Interferon Gamma for the treatment of idiopathic pulmonary fibrosis (IPF). The clinical trial will take place over a two-year time period.
The I-neb device uses Respironics’ AAD technology, which reportedly is an “intelligent” inhalation technology that continually monitors and automatically adapts to an individual patient's breathing pattern to deliver a precise medication dose during the patient's inhalation phase. The result is precise, reproducible dosing of medication to each patient, regardless of his/her breathing pattern, according to the company.
The I-neb AAD System is Respironics’ third generation AAD System and is smaller, quieter and more portable than earlier product generations, notes a company spokesperson. The device weighs less than eight ounces and can be carried in a purse, pocket or briefcase. The I-neb device also provides audible and visual feedback to the patient informing the patient when the treatment is complete.